Montelukast Bluefish

Montelukast, the active ingredient in Montelukast Bluefish, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is employed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as directed by a healthcare professional. The medication is formulated to be taken once daily, with or without food, and is available in tablet form complying with EU regulatory standards.

GNH USA supplies Montelukast Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction.

Asthma: reduces frequency of wheezing episodes and improves overall lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergen exposure. Exercise‑induced bronchoconstriction: prevents narrowing of the airways during or after physical activity. Seasonal allergic rhinitis: provides symptom relief during pollen seasons.

Montelukast may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache reported in clinical use. - Abdominal pain: occasional stomach discomfort or cramps. - Nausea: feeling of queasiness without vomiting. - Cough: transient dry cough. - Dizziness: light‑headed sensation. - Fatigue: unusual tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests indicating possible liver involvement.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

- Assess liver function: evaluate hepatic status before initiating therapy, especially in patients with known liver disease. - Monitor neuropsychiatric symptoms: watch for mood changes, depression, or suicidal ideation during treatment. - Use caution in severe hepatic impairment: dose adjustment may be required or alternative therapy considered. - Avoid in known hypersensitivity: discontinue if allergic reaction to Montelukast or any excipients occurs. - Consider renal function: adjust dosing in patients with significant renal impairment as recommended. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Ritonavir: strong CYP3A4 inhibition can increase Montelukast plasma levels. - Ketoconazole: potent CYP3A4 inhibitor may raise drug exposure. - Erythromycin: macrolide antibiotic that can elevate Montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Theophylline: may experience increased side effects; observe respiratory status. - Corticosteroids: concurrent use may enhance immunosuppressive risk; assess clinical response.